The most known strategy for the treatment of osteoarthritis (OA) and RA is the application of angiogenesis inhibitors, which interfere with the binding of VEGFA to its receptor (VEGFR) by various strategies and inhibit the subsequent VEGFA–VEGFR signaling (e.g., bevacizumab (Avastin®) [202], sorafenib, and sunitinib [203]). The gene discussed is KDR; the disease is rheumatoid arthritis.